Effect of IL-6 and hsCRP Serum Levels on Functional Prognosis in Stroke Patients Undergoing IV-Thrombolysis: Retrospective Analysis

Hanna Pawluk,1 Grzegorz Grześk,2 Renata Kołodziejska,1 Mariusz Kozakiewicz,3 Alina Woźniak,1 Elżbieta Grzechowiak,4 Maciej Szumny,4 Piotr Sobolewski,5 Leszek Bieniaszewski,6 Grzegorz Kozera6 1Department of Medical Biology and Biochemistry, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolau...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pawluk H, Grześk G, Kołodziejska R, Kozakiewicz M, Woźniak A, Grzechowiak E, Szumny M, Sobolewski P, Bieniaszewski L, Kozera G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	inflammatory markers ischemic stroke thrombolysis old age diseases Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/f45ad77481374bef9b8edea1d7e295c0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f45ad77481374bef9b8edea1d7e295c0
record_format	dspace
institution	DOAJ
collection	DOAJ
language	EN
topic	inflammatory markers ischemic stroke thrombolysis old age diseases Geriatrics RC952-954.6
spellingShingle	inflammatory markers ischemic stroke thrombolysis old age diseases Geriatrics RC952-954.6 Pawluk H Grześk G Kołodziejska R Kozakiewicz M Woźniak A Grzechowiak E Szumny M Sobolewski P Bieniaszewski L Kozera G Effect of IL-6 and hsCRP Serum Levels on Functional Prognosis in Stroke Patients Undergoing IV-Thrombolysis: Retrospective Analysis
description	Hanna Pawluk,1 Grzegorz Grześk,2 Renata Kołodziejska,1 Mariusz Kozakiewicz,3 Alina Woźniak,1 Elżbieta Grzechowiak,4 Maciej Szumny,4 Piotr Sobolewski,5 Leszek Bieniaszewski,6 Grzegorz Kozera6 1Department of Medical Biology and Biochemistry, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland; 2Department of Cardiology and Clinical Pharmacology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland; 3Department of Geriatrics, Division of Biochemistry and Biogerontology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland; 4Department of Neurology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland; 5Department of Neurology and Stroke Unit, Holy Spirit Specialist Hospital in Sandomierz, Jan Kochanowski University, Kielce, Poland; 6Medical Stimulation Center, Medical University of Gdańsk, Gdańsk, PolandCorrespondence: Hanna Pawluk Department of Medical Biology and Biochemistry, Faculty of MedicineCollegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Karłowicza 24, Bydgoszcz 85– 092, PolandTel +48 52 585 37 55Email hannapawluk1@wp.plPurpose: We evaluated the relationship between pretreatment IL-6 and hsCRP levels, symptom severity and functional outcome of patients with acute ischemic stroke (AIS) treated with IV-thrombolysis.Patients and Methods: IL-6 and hsCRP samples were obtained from 83 consecutively treated Caucasian patients with AIS prior to initiation of IV-thrombolysis. Severity of stroke symptoms was assessed using the National Institutes of Health Stroke Scale (NIHSS), whereas functional outcome was assessed with modified Rankin Scale (mRS). The commercially available sets of enzymatic immune tests were used to estimate the concentrations of inflammatory markers in serum.Results: Medians of IL-6 serum concentrations prior to IV-thrombolysis were lower in patients with favorable (mRS 0– 2 pts) functional outcome than in those with unfavorable (mRS 3– 6 pts) functional outcome, both at hospital dismission (5.92: 2.30– 7.71 vs 9.46: 3.79– 17.29 pg/mL; p< 0.01) and on the ninetieth day from stroke onset (5.87: 2.30– 10.58 vs 10.9: 5.94– 17.28 pg/mL; p< 0.01). There were no existing differences regarding hsCRP levels between groups (2.49: 0.11– 9.82 vs 4.44: 0.32– 9.87 mg/dL; p=0.30 and 2.57: 0.11– 2.57 vs 2.83: 0.32– 9.32 mg/dL; p=0.75, respectively). Patients with lacunar strokes were characterized by lower median of IL-6 (5.96: 2.87– 13.0% vs 7.29: 2.30– 17.28; p=< 0.02) and hsCRP (2.25: 0.11– 9.82 vs 4.84: 0.35– 9.87; p=0.01) than those with nonlacunar infarctions. Multivariate analysis showed an impact of IL-6 on mRS measured on hospital dismission and after three months, regardless of their initial NIHSS, presence of hemorrhagic transformation and type 2 diabetes. No impact of hsCRP, lacunar etiology and patients’ age on functional outcome existed.Conclusion: Regardless of the stroke etiology, pretreatment of IL-6, but not of hsCRP levels, may help to predict functional outcome after IV-thrombolysis independently of symptom severity and stroke complications.Keywords: inflammatory markers, ischemic stroke, thrombolysis, old age diseases
format	article
author	Pawluk H Grześk G Kołodziejska R Kozakiewicz M Woźniak A Grzechowiak E Szumny M Sobolewski P Bieniaszewski L Kozera G
author_facet	Pawluk H Grześk G Kołodziejska R Kozakiewicz M Woźniak A Grzechowiak E Szumny M Sobolewski P Bieniaszewski L Kozera G
author_sort	Pawluk H
title	Effect of IL-6 and hsCRP Serum Levels on Functional Prognosis in Stroke Patients Undergoing IV-Thrombolysis: Retrospective Analysis
title_short	Effect of IL-6 and hsCRP Serum Levels on Functional Prognosis in Stroke Patients Undergoing IV-Thrombolysis: Retrospective Analysis
title_full	Effect of IL-6 and hsCRP Serum Levels on Functional Prognosis in Stroke Patients Undergoing IV-Thrombolysis: Retrospective Analysis
title_fullStr	Effect of IL-6 and hsCRP Serum Levels on Functional Prognosis in Stroke Patients Undergoing IV-Thrombolysis: Retrospective Analysis
title_full_unstemmed	Effect of IL-6 and hsCRP Serum Levels on Functional Prognosis in Stroke Patients Undergoing IV-Thrombolysis: Retrospective Analysis
title_sort	effect of il-6 and hscrp serum levels on functional prognosis in stroke patients undergoing iv-thrombolysis: retrospective analysis
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/f45ad77481374bef9b8edea1d7e295c0
work_keys_str_mv	AT pawlukh effectofil6andhscrpserumlevelsonfunctionalprognosisinstrokepatientsundergoingivthrombolysisretrospectiveanalysis AT grzeskg effectofil6andhscrpserumlevelsonfunctionalprognosisinstrokepatientsundergoingivthrombolysisretrospectiveanalysis AT kołodziejskar effectofil6andhscrpserumlevelsonfunctionalprognosisinstrokepatientsundergoingivthrombolysisretrospectiveanalysis AT kozakiewiczm effectofil6andhscrpserumlevelsonfunctionalprognosisinstrokepatientsundergoingivthrombolysisretrospectiveanalysis AT wozniaka effectofil6andhscrpserumlevelsonfunctionalprognosisinstrokepatientsundergoingivthrombolysisretrospectiveanalysis AT grzechowiake effectofil6andhscrpserumlevelsonfunctionalprognosisinstrokepatientsundergoingivthrombolysisretrospectiveanalysis AT szumnym effectofil6andhscrpserumlevelsonfunctionalprognosisinstrokepatientsundergoingivthrombolysisretrospectiveanalysis AT sobolewskip effectofil6andhscrpserumlevelsonfunctionalprognosisinstrokepatientsundergoingivthrombolysisretrospectiveanalysis AT bieniaszewskil effectofil6andhscrpserumlevelsonfunctionalprognosisinstrokepatientsundergoingivthrombolysisretrospectiveanalysis AT kozerag effectofil6andhscrpserumlevelsonfunctionalprognosisinstrokepatientsundergoingivthrombolysisretrospectiveanalysis
_version_	1718398159360622592
spelling	oai:doaj.org-article:f45ad77481374bef9b8edea1d7e295c02021-12-02T09:26:55ZEffect of IL-6 and hsCRP Serum Levels on Functional Prognosis in Stroke Patients Undergoing IV-Thrombolysis: Retrospective Analysis1178-1998https://doaj.org/article/f45ad77481374bef9b8edea1d7e295c02020-08-01T00:00:00Zhttps://www.dovepress.com/effect-of-il-6-and-hscrp-serum-levels-on-functional-prognosis-in-strok-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Hanna Pawluk,1 Grzegorz Grześk,2 Renata Kołodziejska,1 Mariusz Kozakiewicz,3 Alina Woźniak,1 Elżbieta Grzechowiak,4 Maciej Szumny,4 Piotr Sobolewski,5 Leszek Bieniaszewski,6 Grzegorz Kozera6 1Department of Medical Biology and Biochemistry, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland; 2Department of Cardiology and Clinical Pharmacology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland; 3Department of Geriatrics, Division of Biochemistry and Biogerontology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland; 4Department of Neurology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland; 5Department of Neurology and Stroke Unit, Holy Spirit Specialist Hospital in Sandomierz, Jan Kochanowski University, Kielce, Poland; 6Medical Stimulation Center, Medical University of Gdańsk, Gdańsk, PolandCorrespondence: Hanna Pawluk Department of Medical Biology and Biochemistry, Faculty of MedicineCollegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Karłowicza 24, Bydgoszcz 85– 092, PolandTel +48 52 585 37 55Email hannapawluk1@wp.plPurpose: We evaluated the relationship between pretreatment IL-6 and hsCRP levels, symptom severity and functional outcome of patients with acute ischemic stroke (AIS) treated with IV-thrombolysis.Patients and Methods: IL-6 and hsCRP samples were obtained from 83 consecutively treated Caucasian patients with AIS prior to initiation of IV-thrombolysis. Severity of stroke symptoms was assessed using the National Institutes of Health Stroke Scale (NIHSS), whereas functional outcome was assessed with modified Rankin Scale (mRS). The commercially available sets of enzymatic immune tests were used to estimate the concentrations of inflammatory markers in serum.Results: Medians of IL-6 serum concentrations prior to IV-thrombolysis were lower in patients with favorable (mRS 0– 2 pts) functional outcome than in those with unfavorable (mRS 3– 6 pts) functional outcome, both at hospital dismission (5.92: 2.30– 7.71 vs 9.46: 3.79– 17.29 pg/mL; p< 0.01) and on the ninetieth day from stroke onset (5.87: 2.30– 10.58 vs 10.9: 5.94– 17.28 pg/mL; p< 0.01). There were no existing differences regarding hsCRP levels between groups (2.49: 0.11– 9.82 vs 4.44: 0.32– 9.87 mg/dL; p=0.30 and 2.57: 0.11– 2.57 vs 2.83: 0.32– 9.32 mg/dL; p=0.75, respectively). Patients with lacunar strokes were characterized by lower median of IL-6 (5.96: 2.87– 13.0% vs 7.29: 2.30– 17.28; p=< 0.02) and hsCRP (2.25: 0.11– 9.82 vs 4.84: 0.35– 9.87; p=0.01) than those with nonlacunar infarctions. Multivariate analysis showed an impact of IL-6 on mRS measured on hospital dismission and after three months, regardless of their initial NIHSS, presence of hemorrhagic transformation and type 2 diabetes. No impact of hsCRP, lacunar etiology and patients’ age on functional outcome existed.Conclusion: Regardless of the stroke etiology, pretreatment of IL-6, but not of hsCRP levels, may help to predict functional outcome after IV-thrombolysis independently of symptom severity and stroke complications.Keywords: inflammatory markers, ischemic stroke, thrombolysis, old age diseasesPawluk HGrześk GKołodziejska RKozakiewicz MWoźniak AGrzechowiak ESzumny MSobolewski PBieniaszewski LKozera GDove Medical Pressarticleinflammatory markersischemic strokethrombolysisold age diseasesGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 15, Pp 1295-1303 (2020)

Effect of IL-6 and hsCRP Serum Levels on Functional Prognosis in Stroke Patients Undergoing IV-Thrombolysis: Retrospective Analysis

Ejemplares similares